What Is Tirzepatide? Brand Names, Uses, Side Effects & Cost

Tirzepatide is a once-weekly prescription shot sold under two U.S. brand names. Zepbound is approved for adult weight management and obesity-related sleep apnea. Mounjaro is approved for type 2 diabetes from age 10 and heart-risk reduction in certain adults. No FDA-approved generic or pill was found. Cash-pay Zepbound starts at $299 per 28-day supply.

Which name you'd get depends on why you need it, what your prescriber orders, and how you'll pay. Even the device matters. Eligible Medicare Part D members may get Zepbound KwikPen for weight management through the $50 Medicare GLP-1 Bridge. If an ad says only "tirzepatide" at a much lower price, ask whether it is Zepbound, Mounjaro, compounded, or an unapproved product before paying. The decoder below sorts out every name you might see.

Bottom line: In the U.S., the FDA-approved tirzepatide products are Zepbound and Mounjaro. The reason for treatment points to the brand; the prescriber and coverage rules decide the exact product and form.

Best for: Zepbound fits adults who meet its weight-management criteria or have moderate-to-severe sleep apnea with obesity. Mounjaro fits people age 10 and older with type 2 diabetes and certain high-risk adults who need cardiovascular-risk reduction.

Not best for: Anyone under 18 seeking tirzepatide for weight management, people looking for a pill, and anyone with a personal or family history of medullary thyroid cancer or MEN 2. Neither brand is approved for type 1 diabetes.

The factor that matters most: The condition being treated and the exact product your plan covers. Both brands contain tirzepatide, but they have separate labels, prescriptions, product identifiers, and coverage rules.

Every Tirzepatide Brand Name, Decoded

Tirzepatide is the medicine's own name, not a brand. In the U.S., the FDA has approved it only inside two Eli Lilly brands, Zepbound and Mounjaro. Each brand comes in a few forms, like a pen or a vial, but a form is not a new drug.

Doctors call "tirzepatide" the nonproprietary or generic name. That just means the name of the medicine itself. Think "ibuprofen" versus "Advil." The brand is the name on the box.

Table 1. The real FDA-approved tirzepatide products (checked September 24, 2026)

Sources: Zepbound label on DailyMed (updated August 28, 2026) and Mounjaro label on DailyMed (updated August 27, 2026).

Table 2. Look-alike names that are not a U.S. tirzepatide brand

One question clears up most confusion: "Is this Zepbound, Mounjaro, or compounded?"

Which Tirzepatide Brand Name Should You Ask About?

Ask about Zepbound if your goal is weight loss or sleep apnea with obesity. Ask about Mounjaro if you have type 2 diabetes. If more than one reason fits you, the labels, your health history, and your plan's rules decide, and a licensed clinician makes the call.

Here's the honest part. We can't tell you which brand a clinician will prescribe or which one your plan will cover. No page can. A licensed clinician decides, and your plan's current rules matter. What we can do is show you the current labels and the fastest next question to ask.

Three quick checks point you the right way:

• Your BMI. Zepbound is for a BMI of 30 or higher, or 27 or higher with a condition like high blood pressure. Not sure of yours? Use our BMI eligibility calculator.
• Your insurance type. A card from a job, or one you bought yourself, is usually commercial. A card that says Medicare, Medicaid, or TRICARE is a government plan.
• Shot or pill. Both tirzepatide brands are weekly shots.

The right GLP-1 path isn't the same for everyone. It depends on your state, your insurance, your budget, whether you want FDA-approved or compounded medicine, and whether you want a shot or a pill. Our free Find My GLP-1 Path tool asks 8 quick questions plus a state and age check, then shows the access route and provider options that fit your goals, budget, and preferences. It takes about 2 minutes, and you don't need to sign up or give an email to see your match. A licensed clinician makes all treatment decisions.

See your GLP-1 match in about 2 minutes

Is Zepbound the Same as Mounjaro?

Both contain tirzepatide in the same six dose strengths, and both are made by Eli Lilly. But they are separate FDA-approved products with separate labels and approved uses. Sharing a drug substance does not make the finished products, prescriptions, or insurance rules interchangeable.

Think of tirzepatide as an ingredient. Zepbound and Mounjaro are two labeled products made with it. The label defines each product's approved jobs, and the exact product and form often decide how coverage works.

Sources: both labels above, LillyDirect's Zepbound page, LillyDirect's Mounjaro page, Mounjaro savings terms, and the Medicare GLP-1 Bridge.

Can Mounjaro be used for weight loss?

Mounjaro's U.S. label does not include weight management. Clinicians can prescribe an approved drug outside its label, but the FDA-approved tirzepatide product for weight management is Zepbound. Coverage often turns on the exact product and approved use.

Can you take Zepbound and Mounjaro together?

Zepbound's label says coadministration with another tirzepatide-containing product or any GLP-1 receptor agonist is not recommended. Do not combine or switch Zepbound and Mounjaro on your own. Your prescriber decides how to change products.

Is Zepbound stronger than Mounjaro?

Neither brand is universally "stronger." They use the same six dose strengths, but they were studied under different labels in different groups. The useful question is which product matches the condition, medical history, and coverage—not which logo is stronger.

What Is Tirzepatide Used For?

Tirzepatide has four FDA-approved uses, split across two brands. Zepbound covers weight management and sleep apnea with obesity. Mounjaro covers type 2 diabetes and, since August 2026, lowering heart risk in some adults with type 2 diabetes.

Weight management (Zepbound)

Zepbound is approved, along with a lower-calorie diet and more activity, to help adults lose extra weight and keep it off. It's for adults with obesity, or adults with overweight plus at least one weight-related condition. The FDA's approval notice defines that as a BMI of 30 or higher, or 27 or higher with a condition like high blood pressure, type 2 diabetes, or high cholesterol.

Meeting the BMI rule doesn't guarantee a prescription. A clinician still reviews your health history.

Sleep apnea (Zepbound)

Zepbound is also approved to treat moderate to severe obstructive sleep apnea in adults with obesity. Sleep apnea means your breathing stops and starts while you sleep. The FDA added this use in December 2024. It doesn't mean every person with sleep apnea qualifies, and it doesn't replace other sleep apnea care on its own.

Type 2 diabetes (Mounjaro)

Mounjaro is approved, with diet and exercise, to improve blood sugar in adults and children 10 and older with type 2 diabetes. In the SURPASS-1 trial, A1C fell 1.7 to 1.8 points over 40 weeks, compared with 0.1 on placebo. A1C is a blood test that shows your average blood sugar over about three months.

Heart-risk reduction (Mounjaro, new in August 2026)

On August 27, 2026, the FDA approved Mounjaro to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk. That means cardiovascular death, a nonfatal heart attack, or a nonfatal stroke.

The approval came from SURPASS-CVOT, which included 13,299 adults with type 2 diabetes and established cardiovascular disease. Over a median 210.1 weeks, a major cardiovascular event occurred in 12.1% of the Mounjaro group and 13.0% of the dulaglutide group. The hazard ratio was 0.92 (95.3% CI 0.83 to 1.01), which met the study's test for noninferiority; it did not prove Mounjaro was superior. Your clinician decides whether the label fits you.

What tirzepatide is not approved for

Neither brand is approved for type 1 diabetes. Zepbound is not approved for anyone under 18. Neither brand is approved as a pill. For dose questions, see our tirzepatide dosing schedule. Your prescriber sets your dose.

Is There a Generic Tirzepatide?

No. As of September 24, 2026, we found no FDA-approved generic tirzepatide. "Tirzepatide" is the medicine's generic name, but a generic name is not the same thing as a generic drug.

What the 2026 generic filings mean

The FDA's Paragraph IV list dated September 14, 2026 shows certifications tied to applications for certain tirzepatide KwikPen strengths (FDA Paragraph IV list). The list includes Mounjaro KwikPen strengths submitted August 24, 2026 and Zepbound KwikPen strengths submitted June 26, August 24, and August 26, 2026.

Here's what that means in plain words. An applicant told the FDA that a listed patent is invalid, unenforceable, or will not be infringed by its proposed product. Patent notice and litigation rules can delay final approval. The filing dates do not show that a generic was approved, launched, or will arrive on a promised date.

A filing is not an approval. We won't guess when a generic will arrive, and you shouldn't trust anyone who promises a date.

Is Compounded Tirzepatide a Brand or a Generic?

Neither. Compounded tirzepatide is prepared by a compounding pharmacy or outsourcing facility, and compounded drugs are not FDA-approved. The FDA says compounded drugs and generic drugs are not the same, and it does not review compounded drugs for safety, effectiveness, or quality before marketing.

A compounded preparation is made under compounding law for a prescription or permitted health-care setting. It is not made under the approved Zepbound or Mounjaro application. There are two main paths:

• 503A pharmacies are state-licensed pharmacies or physicians that compound for identified patients based on valid prescriptions. State pharmacy boards have the main oversight role.
• 503B outsourcing facilities register with the FDA, must follow current good manufacturing practice requirements, and are subject to FDA inspection.

The FDA says compounded drugs should be used only when a patient's medical needs cannot be met by an FDA-approved drug. Some telehealth programs still advertise compounded tirzepatide, but the approved labels and trial results for Zepbound and Mounjaro do not automatically apply to those finished products.

What changed for compounded tirzepatide

FDA rules still leave limited patient-specific compounding paths, but adding B12 or another ingredient does not automatically make a copy lawful or meaningfully different. The exact prescription, pharmacy or outsourcing facility, ingredients, route, and reason matter.

As of May 31, 2026, the FDA had received more than 730 adverse-event reports associated with compounded tirzepatide. The FDA says these reports are likely undercounted because many state-licensed pharmacies do not have to report them. A report does not by itself prove that the compounded product caused the event.

What to check when a website only says "tirzepatide"

Say you're 45, paying cash, and a website offers "tirzepatide" for much less than Zepbound. The word alone doesn't tell you what you're buying. Ask these five things before you pay:

1. The exact product. Does the prescription say Zepbound, Mounjaro, compounded tirzepatide, or something else?
2. Who makes or prepares it. Eli Lilly makes the approved brands. A compounded preparation should name the pharmacy or outsourcing facility.
3. FDA status. Is the finished product FDA-approved, or is it compounded and not FDA-approved?
4. The form and the pharmacy. Pen, vial, KwikPen, tablet, drop, or something else? Which pharmacy fills it?
5. The whole receipt. Medicine, membership, visit, lab, shipping, refill price, commitment, and how to cancel.

A low price does not prove a scam. But an offer should tell you plainly what the finished product is. Our guide on how to verify a compounding pharmacy license walks through the pharmacy check. If you're moving from compounded to a brand, see switching from compounded GLP-1 to a brand-name provider. To compare both routes side by side, see compounded vs. brand-name GLP-1s and telehealth tirzepatide options.

Is There a Tirzepatide Pill?

No FDA-approved tirzepatide pill was identified as of September 24, 2026. The current Mounjaro and Zepbound labels cover shots given under the skin once a week; neither label covers a tirzepatide tablet, drop, gum, or other oral form.

A website selling a tirzepatide pill is not selling an FDA-approved oral version of Zepbound or Mounjaro. If you want a pill, other approved medicines exist, but they are not tirzepatide. Foundayo is Lilly's once-daily orforglipron pill, approved April 1, 2026. Wegovy, a semaglutide brand, also has an approved pill form.

For the full picture, see oral tirzepatide FDA status.

Is a KwikPen a Different Drug?

No. KwikPen is a product presentation, not a different drug. A Zepbound KwikPen or Mounjaro KwikPen is a single-patient-use pen that contains four weekly doses. The brand, approved uses, and six dose strengths stay the same.

Both labels say never to share a KwikPen, even with a new needle. They also say KwikPen is not recommended for self-administration by people with vision impairment. Mounjaro's label adds that pediatric patients should not self-administer Mounjaro KwikPen. Your pharmacist or prescriber should train you on the exact presentation you receive.

Coverage can change by form. When you check with your plan, name the exact form on your prescription.

How Much Does Tirzepatide Cost in 2026?

Your price depends on the brand, presentation, prescription, and payment route. Cash-pay Zepbound KwikPens and single-dose vials start at $299 to $449 per 28-day supply through LillyDirect when the refill rules are met. Mounjaro single-dose pens start at $499/month through LillyDirect. With eligible commercial insurance, manufacturer savings cards may lower either brand to as little as $25.

Zepbound cash prices on LillyDirect (KwikPen or single-dose vial, checked September 24, 2026)

Source: LillyDirect Zepbound, checked September 24, 2026.

Other ways to pay

The Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027. It supplies eligible weight-management drugs outside the normal Part D payment flow. Zepbound's single-dose pens and vials are not included.

The sticker price is not the whole receipt:

• A Lilly Zepbound "month" is 28 days. That is 13 fills over 364 days, not 12 calendar-month fills.
• The 45-day rule. At 7.5 mg and higher, the $449 Zepbound price depends on refilling within 45 days.
• Device supplies cost extra. KwikPens need pen needles. Vials need needles and syringes.
• You still need a prescription. LillyDirect fills prescriptions; it does not replace a clinical evaluation.
• A telehealth membership is separate. For example, Ro publishes a $39 first month, then $149 month to month, or a $74/month equivalent when the $888 annual plan is paid upfront. Medication is billed separately. Ro's published Zepbound KwikPen cash prices match the $299, $399, and $449 manufacturer route when its terms are met (Ro pricing, checked September 24, 2026).

Here is one clean annual example. If 13 Zepbound fills each cost $449, the medicine total over 364 days is 13 × $449 = $5,837. Needles, clinician visits, labs, shipping, taxes, and other fees are extra when they apply. This is price math, not a dosing plan or a prediction of what a prescriber will order.

To compare programs, see brand-name tirzepatide providers and brand-name Zepbound vial routes. For every dose and route, see Zepbound cost without insurance, Mounjaro cost without insurance, and our GLP-1 cost guide.

What Changed for Tirzepatide in 2026?

A lot changed this year. Both labels added KwikPen information, Zepbound's suicidal-behavior and ideation warning was removed, Mounjaro gained a cardiovascular-risk indication, self-pay routes expanded, and FDA listed Paragraph IV certifications for some KwikPen strengths. Pages based on older labels or prices can now be wrong.

The current Zepbound label no longer carries the suicidal-behavior and ideation warning. That correction means older summaries should be updated; it does not replace a clinician's review of a person's full health history.

What We Actually Verified

On September 24, 2026, we read the current Mounjaro label on DailyMed, updated August 27, and the current Zepbound label, updated August 28. We checked FDA approved-drug records and its September 14 Paragraph IV list; FDA's compounding Q&A, shortage-policy page, 503B bulks proposal, and unapproved-GLP-1 safety page; CMS and Medicare GLP-1 Bridge pages; LillyDirect and savings pages for both brands; and Ro's published pricing.

We also checked the primary trial reports or current labels for the outcome tables in this page. Prices and program terms are what the source pages published on the check date. Your prescription, diagnosis, plan rules, prior authorization, pharmacy stock, taxes, fees, and checkout total can differ, so the current source and final checkout control.

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers.

How Does Tirzepatide Work?

Tirzepatide acts like two natural gut hormones, GIP and GLP-1, at the same time. In the approved products, that lowers appetite and food intake, helps the body release insulin when blood sugar is high, and slows how fast the stomach empties.

Here's what those hormones do:

• GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It helps control appetite and how much you eat.
• GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone. It helps your body release insulin when blood sugar rises. Early lab studies suggest it may add to appetite control too. Learn more in what is GIP.

Both hormones have receptors in the parts of the brain that manage appetite. Tirzepatide switches on both. The labels say the stomach-slowing effect is largest after the first dose and fades over time.

Is tirzepatide a GLP-1? Is it a peptide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It's often grouped with GLP-1 drugs because it acts on GLP-1 receptors too. It's also a lab-made peptide, which means a chain of amino acids. It's built on the GIP hormone, with a fatty acid attached that slows how fast your body clears it. Its half-life is about 5 days, meaning half of a dose is gone in about 5 days. That's why it's a once-a-week shot.

All of this comes from the Zepbound and Mounjaro labels. It describes the approved products, not compounded versions.

How Much Weight Can You Lose on Tirzepatide?

In Zepbound's main 72-week trial in adults without diabetes, average weight loss was 15.0% to 20.9%, depending on dose, versus 3.1% with placebo. People vary a lot. These results come from the approved brand, not compounded versions.

Zepbound Study 1 (SURMOUNT-1): adults with obesity or overweight, no diabetes, 72 weeks

Source: Zepbound label, Table 2.

In a second trial of adults who also had type 2 diabetes, average loss was 12.8% at 10 mg and 14.7% at 15 mg, versus 3.2% with placebo. Everyone in both trials also got diet and activity counseling, aiming for about 500 fewer calories a day and at least 150 minutes of activity a week.

These are group averages from controlled trials. They are not a promise for any one person.

What Happens If You Stop Taking Tirzepatide?

Weight regain was substantial in the SURMOUNT-4 randomized-withdrawal trial. Everyone first received tirzepatide for 36 weeks. From week 36 to week 88, the group switched to placebo regained an average 14.0% of body weight, while the group that continued tirzepatide lost another 5.5% (JAMA).

That doesn't mean the medicine failed. Obesity acts like a long-term condition, similar to high blood pressure. If you're thinking about stopping, talk with your clinician first. See what happens when you stop a GLP-1.

Tirzepatide Side Effects and Who Should Not Take It

The most common side effects are stomach-related, like nausea, diarrhea, vomiting, and constipation. They show up most while the dose is going up and often ease over time. Both labels carry a boxed warning about thyroid tumors seen in rats.

Common side effects in Zepbound's weight-loss trials (percent of people)

Source: Zepbound label, Table 1. Hair loss was tied to weight loss and was more common in women. In Mounjaro's diabetes trials, nausea affected 12% to 18% of people on Mounjaro versus 4% on placebo.

Who should not take tirzepatide

Both labels say don't use tirzepatide if you have:

• A personal or family history of medullary thyroid cancer, or a condition called MEN 2 (multiple endocrine neoplasia type 2)
• A known serious allergy to tirzepatide or any ingredient in the product

Also talk with your clinician if you are pregnant or planning a pregnancy. Zepbound's label says to stop it when pregnancy is recognized. Mounjaro's label says animal studies suggest it may cause fetal harm. Neither brand is approved for type 1 diabetes, and Zepbound is not approved for anyone under 18. For the full list, see GLP-1 contraindications.

Serious warnings on the labels

• Pancreatitis. Severe belly pain that won't go away, sometimes spreading to the back, with or without vomiting.
• Gallbladder problems. These have happened in trials and are linked to weight loss.
• Kidney injury from dehydration. Vomiting and diarrhea can dry you out.
• Serious allergic reactions. Swelling of the face or throat, or trouble breathing.
• Low blood sugar. The risk is higher with insulin or sulfonylurea diabetes pills.
• Eye changes. People with diabetic retinopathy should be checked for worsening.
• Anesthesia. Food can stay in the stomach longer, so tell your surgery team you take it. See when to stop a GLP-1 before surgery.
• Severe stomach problems. Neither brand is recommended for people with severe gastroparesis, which means a very slow-emptying stomach.

The labels also say birth control pills may work less well at first. They advise switching to a non-pill method, or adding a barrier method, for 4 weeks after starting and after each dose increase. See GLP-1s and birth control pills.

When to get help

Call your prescriber right away for a lump or swelling in your neck, trouble swallowing, a hoarse voice that won't go away, or shortness of breath. Do the same for severe belly pain that won't stop, or vomiting and diarrhea you can't keep up with. Call 911 for swelling of the face or throat or trouble breathing.

Is tirzepatide safe long term?

SURPASS-CVOT followed 13,299 adults with type 2 diabetes and established cardiovascular disease for a median 210.1 weeks, about four years. The current Mounjaro label reports no new safety signals in that study, but it does not settle every long-term question for every population. Research continues. More detail is in our tirzepatide side effects and Mounjaro side effects guides.

Tirzepatide vs. Semaglutide: Different Medicines, Different Brands

Semaglutide is a different medicine, sold as Ozempic and Wegovy by Novo Nordisk. It acts on GLP-1 only, while tirzepatide acts on GIP and GLP-1. In a head-to-head trial, tirzepatide produced more average weight loss.

In the SURMOUNT-5 trial, 751 adults with obesity but without diabetes were assigned to maximum tolerated tirzepatide or semaglutide. At 72 weeks, average weight change was −20.2% with tirzepatide and −13.7% with semaglutide (New England Journal of Medicine).

More trial results don't make one medicine right for everyone. Side effects, health history, and coverage matter too. For the full comparison, see semaglutide vs. tirzepatide.

Tirzepatide Brand Name FAQ

What are the two brand names for tirzepatide? Zepbound and Mounjaro, both made by Eli Lilly. Zepbound is approved for weight management and for sleep apnea in adults with obesity. Mounjaro is approved for type 2 diabetes and for lowering heart risk in some adults with type 2 diabetes.

Is tirzepatide the same as Zepbound? Zepbound contains tirzepatide, but Zepbound is the name of a specific FDA-approved finished product with its own label. Mounjaro also contains tirzepatide under a separate label for different uses.

Is there another name for Zepbound? In the U.S., Mounjaro is the other approved brand that contains tirzepatide, but it has different labeled uses. In the UK and EU, local Mounjaro labels also include weight management. In India, tirzepatide is sold under Mounjaro and Yurpeak, subject to local labels.

Is there a generic tirzepatide? No. We found no FDA-approved generic as of September 24, 2026. Generic makers have filed with the FDA for some KwikPen strengths, but a filing is not an approval.

Is there a tirzepatide pill? No FDA-approved one. Both brands are once-weekly shots. Foundayo is an FDA-approved daily pill from Lilly, but it's a different medicine called orforglipron.

Which tirzepatide brand is for weight loss? Zepbound. Mounjaro's label covers type 2 diabetes and heart-risk reduction, not weight management. A clinician can prescribe outside a label, but coverage may depend on the exact product, approved use, and plan rules.

Is tirzepatide the generic name for Mounjaro? Yes, in the everyday sense. "Tirzepatide" is the medicine's own name, and Mounjaro and Zepbound are brand names. That doesn't mean a generic version is for sale.

Is compounded tirzepatide the same as Mounjaro or Zepbound? No. Compounded drugs are not FDA-approved, and the FDA says they are not the same as generic drugs. The brands' trial results and labels don't carry over to compounded products.

Can Mounjaro and Zepbound be used together? Zepbound's label says coadministration with another tirzepatide-containing product or any GLP-1 receptor agonist is not recommended. Do not combine or switch Mounjaro and Zepbound on your own; your prescriber decides.

What if I have type 2 diabetes and obesity? Don't choose by brand name alone. Your main goal, health history, other medicines, and plan rules all matter. The product your plan covers for diabetes may differ from the one it covers for weight.

Is KwikPen another brand of tirzepatide? No. KwikPen is a pen that holds four weekly doses. A Zepbound KwikPen is still Zepbound, and a Mounjaro KwikPen is still Mounjaro.

Which name should I give my insurance company? Use the exact product and form on your prescription, like "Zepbound single-dose pen" or "Zepbound KwikPen." Ask if that exact product is on your plan's drug list. Also ask if it needs prior authorization, which is a permission slip from your insurer before it pays.

How much does tirzepatide cost without insurance? Through LillyDirect, Zepbound KwikPens and single-dose vials start at $299 at 2.5 mg, $399 at 5 mg, and $449 at higher doses per 28-day supply when the refill rule is met. Outside the 45-day window, 7.5 mg is $499 and 10 mg through 15 mg are $699. Mounjaro single-dose pens start at $499/month through LillyDirect. Device supplies and clinical fees may cost extra.

Is tirzepatide FDA-approved? Yes, but only as specific finished products: Mounjaro, first approved in 2022, and Zepbound, first approved in 2023. The approval does not belong to every product labeled only "tirzepatide." Compounded tirzepatide is not FDA-approved.

Still not sure which GLP-1 path fits you? Take our free Find My GLP-1 Path quiz — about 2 minutes, no signup.

Find My GLP-1 Path

Sources

All sources checked September 24, 2026 unless another date is stated.

1. Mounjaro (tirzepatide) prescribing information, DailyMed, updated August 27, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
2. Zepbound (tirzepatide) prescribing information, DailyMed, updated August 28, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
3. FDA Drugs@FDA, Mounjaro NDA 215866 and Zepbound NDA 217806 approval history. https://www.accessdata.fda.gov/scripts/cder/daf/
4. LillyDirect, Zepbound self-pay pricing and terms. https://www.lilly.com/lillydirect/zepbound
5. LillyDirect, Mounjaro self-pay pricing and terms. https://www.lilly.com/lillydirect/mounjaro
6. Lilly, Mounjaro savings and coverage terms. https://mounjaro.lilly.com/savings-coverage
7. Lilly, Zepbound savings and coverage terms. https://zepbound.lilly.com/savings
8. CMS, Medicare GLP-1 Bridge overview and provider/pharmacy FAQs. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
9. Medicare, weight-loss drug coverage under the Medicare GLP-1 Bridge. https://www.medicare.gov/coverage/weight-loss-drugs
10. FDA, Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
11. FDA, tirzepatide shortage resolution and current compounding policy. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
12. FDA, concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
13. FDA, Paragraph IV patent certifications, list dated September 14, 2026. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/patent-certifications-and-suitability-petitions
14. FDA, April 30, 2026 proposal on the 503B bulks list. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
15. FDA, Zepbound chronic-weight-management approval notice. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
16. FDA, Foundayo (orforglipron) approval announcement, April 1, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
17. Lilly, Zepbound KwikPen availability, February 23, 2026. https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-most-prescribed-weight-management
18. Ro, weight-management membership and medication pricing. https://ro.co/weight-loss/pricing/
19. Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: SURMOUNT-4. JAMA. https://jamanetwork.com/journals/jama/fullarticle/2812936
20. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity: SURMOUNT-5. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
21. European Medicines Agency, Mounjaro EPAR. https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro
22. UK MHRA, Mounjaro authorization for weight management. https://www.gov.uk/government/news/mounjaro-authorised-to-treat-weight-management-in-the-uk
23. Cipla, Yurpeak (tirzepatide) launch in India, December 10, 2025. https://www.cipla.com/press-releases-statements/cipla-launches-yurpeakr-tirzepatide-treatment-obesity-and-type-2-diabetes
24. Wegovy (semaglutide) prescribing information, including the oral tablet presentation. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b